The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro
Launched by GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE · Nov 28, 2022
Trial Information
Current as of January 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Sign an informed consent form before any research-related activities;
- • 2. No gender restrictions, age ≥18 years old, and ≤75 years old;
- 3. Patients who need to receive whole lung lavage due to the needs of the disease, and the patient agrees to perform whole lung lavage. The standards are as follows:
- • 1. The diagnosis of aPAP is clear, and the anti-GM-CSF antibody in serum is greater than 5 μg/ml;
- • 2. PaO2 \<65 mmHg;
- • 3. P(A-a)O2\>40 mmHg;
- • 4. Intrapulmonary shunt \>10%-12%.
- Exclusion Criteria:
- • 1. Suffering from multiple chronic respiratory diseases at the same time, including but not limited to chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma;
- • 2. Various malignant tumors or a history of malignant tumors;
- • 3. Uncontrolled pulmonary or systemic infection;
- • 4. Severe other systemic diseases: acute myocardial infarction, unstable angina pectoris, liver cirrhosis, acute glomerulonephritis, etc.;
- • 5. Syphilis, HIV, HCV antibody positive;
- • 6. Patients with coagulation disorders who cannot perform bronchoscopy, such as hemophilia, giant platelet syndrome, thrombocytopenia, etc.;
- • 7. Severe renal impairment, serum creatinine \> 1.5 times the upper limit of normal;
- • 8. Liver disease or liver function damage: ALT, AST, total bilirubin \> 2 times the upper limit of normal;
- • 9. Have any coexisting medical conditions or diseases that the investigators judge may impair the development of this trial;
- • 10. Social and mental disability, no legal capacity/limited capacity;
- • 11. Refuse to sign the informed consent.
- • -
About Guangzhou Institute Of Respiratory Disease
The Guangzhou Institute of Respiratory Disease is a leading research institution dedicated to advancing the understanding and treatment of respiratory diseases. With a strong focus on clinical trials, the Institute aims to develop innovative therapeutic strategies and improve patient outcomes through rigorous scientific inquiry. Committed to excellence in respiratory health, it collaborates with national and international partners to conduct cutting-edge research, fostering an environment of collaboration and knowledge exchange. The Institute plays a pivotal role in shaping respiratory medicine through its dedication to high-quality clinical research, training, and public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials